The American Journal of Managed Care

Complement Inhibitors Suggested to Benefit Treatment Outcomes in PNH

A meta-analysis on complement inhibitors in the management of paroxysmal nocturnal hemoglobinuria (PNH) reveals an association between these interventions and positive treatment outcomes. Complement ...
Business Wire

Empaveli is the first treatment for PNH that binds to the complement protein C3.

SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, ...
The American Journal of Managed Care

Complement Inhibitors may be Ineffective for Reducing Omicron Infection Severity

A single-center study suggests complement inhibitors do not reduce the severity of a COVID-19 Omicron infection in patients with paroxysmal nocturnal hemoglobinuria (PNH). A COVID-19 infection can ...
Healio

Q&A: ‘Patient-centered care’ at core of treatment for paroxysmal nocturnal hemoglobinuria

In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...
Nasdaq

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH

Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients1-5 In APPLY-PNH, patients ...
MedPage Today

In Patients with PNH, Respiratory Infections Contribute to Breakthrough Hemolysis

Patients who are taking complement inhibitors may still experience breakthrough hemolysis associated with respiratory viral infections. Patients with PNH should be closely monitored for signs of ...
WebMD

Empaveli for Paroxysmal Nocturnal Hemoglobinuria: What You Need to Know

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare immune disease that causes your body to break down red blood cells when it should not. This disorder happens when there is a problem with certain ...
MedPage Today

Thrombotic Events in Paroxysmal Nocturnal Hemoglobinuria

A recent study found that thrombotic events occurred in 3 out of 26 patients who received eculizumab, compared with 3 out of 13 who did not receive the therapy. Some symptoms, including abdominal ...
MedCity News

Novo Nordisk Gets New Complement System Approach to Rare Diseases With Deal for Omeros Drug

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
Nasdaq

Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

Basel, December 8, 2022 — Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 ...
Business Wire

FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...
Seeking Alpha

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...